| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
Purity: ≥98%
Tanshinone I (Tanshinone A; dihydrotanshinone, tanshinone IIA), a natural pigment isolated from the herbal medicine Salvia miltiorrhiza Bunge, is a potent inhibitor of type IIA human recombinant sPLA2 with important biological activity. It inhibits type IIA human recombinant sPLA2 and rabbit recombinant cPLA2 with IC50s of 11 μM and 82 μM, respectively. It is an active component that may have anticancer, antidiabetic, and neuroprotective properties. Tanshinone I displays cytotoxicity against human macrophages and IFN-g production in KLH-primed lymph node cells. Tanshinone I inhibits PGE2 formation from LPS-induced RAW macrophages (IC50 = 38 μM).
| ln Vitro |
Tanshinone I (IC50=38 μM) suppresses the production of PGE2 in RAW macrophages stimulated by LPS. Tanshinone I clearly reduces PGE2 synthesis (IC50=38 μM) at 10-100 μM when applied concurrently with LPS. When tanshinone I is administered after COX-2 is fully activated, it also lowers PGE2 (IC50=46 μM). Tanshinone I may directly reduce COX-2 activity and/or influence PLA2 activity, as evidenced by the fact that it inhibits PGE2 synthesis by pre-induced COX-2. Tanshinone I exhibits concentration-dependent inhibition of sPLA2 (IC50=11 μM) when it is treated with two distinct forms of phospholipase A2 (PLA2). Tanshinone I also suppresses cPLA2 (IC50=82 μM), albeit less potently [1].
|
||
|---|---|---|---|
| ln Vivo |
In paw oedema and adjuvant-induced arthritis in rats, tanshinone I exhibits anti-inflammatory properties. Rat carrageenan (CGN)-induced paw oedema and rat adjuvant-induced arthritis (AIA) are two standard animal models of acute and chronic inflammation that are used to determine the anti-inflammatory efficacy of Tanshinone I. While indomethacin's IC50 is 7.1 mg/kg, tanshinone I exhibits considerable anti-inflammatory efficacy against CGN-induced paw oedema (47% inhibition at 160 mg/kg). With an oral dosage of 50 mg/kg/day in AIA, tanshinone I inhibits secondary inflammation by 27% at 18 days, while prednisolone (5 mg/kg/day) exhibits a strong 65% inhibition [1].
|
||
| Animal Protocol |
|
||
| References | |||
| Additional Infomation |
Tanshinone I is an abietane diterpenoid. It has a role as an anticoronaviral agent.
Tanshinone I has been reported in Salvia miltiorrhiza, Salvia sclarea, and other organisms with data available. See also: Salvia Miltiorrhiza Root (part of). |
| Molecular Formula |
C18H12O3
|
|
|---|---|---|
| Molecular Weight |
276.29
|
|
| Exact Mass |
276.078
|
|
| CAS # |
568-73-0
|
|
| Related CAS # |
|
|
| PubChem CID |
114917
|
|
| Appearance |
Light brown to black solid powder
|
|
| Density |
1.3±0.1 g/cm3
|
|
| Boiling Point |
498.0±24.0 °C at 760 mmHg
|
|
| Melting Point |
233-234ºC
|
|
| Flash Point |
245.9±15.6 °C
|
|
| Vapour Pressure |
0.0±1.3 mmHg at 25°C
|
|
| Index of Refraction |
1.676
|
|
| LogP |
4.44
|
|
| Hydrogen Bond Donor Count |
0
|
|
| Hydrogen Bond Acceptor Count |
3
|
|
| Rotatable Bond Count |
0
|
|
| Heavy Atom Count |
21
|
|
| Complexity |
471
|
|
| Defined Atom Stereocenter Count |
0
|
|
| InChi Key |
AIGAZQPHXLWMOJ-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C18H12O3/c1-9-4-3-5-12-11(9)6-7-13-15(12)17(20)16(19)14-10(2)8-21-18(13)14/h3-8H,1-2H3
|
|
| Chemical Name |
1,6-dimethyl-phenanthro[1,2-b]furan-10,11-dione
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6194 mL | 18.0969 mL | 36.1939 mL | |
| 5 mM | 0.7239 mL | 3.6194 mL | 7.2388 mL | |
| 10 mM | 0.3619 mL | 1.8097 mL | 3.6194 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT01452477 | Unknown † | Drug: tanshinone Drug: tanshinone placebo |
Recurrent Glioma Refractory Glioma |
Polycystic Ovary Syndrome | October 2011 | Not Applicable |
| NCT02524964 | Unknown † | Drug: sodium tanshinone IIA sulfonate Other: control |
Left Ventricular Remodeling Acute Myocardial Infarction |
Guangdong Provincial Hospital of Traditional Chinese Medicine |
December 2015 | Phase 4 |
| NCT02200978 | Completed | Drug: ATO Drug: RIF |
Childhood Acute Promyelocytic Leukemia |
South China Children's Leukemia Group | September 2011 | Phase 4 |
 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA